Mindmed to be added to the nasdaq biotechnology index

New york--(business wire)--mind medicine (mindmed) inc. (nasdaq: mnmd), (the "company" or "mindmed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the nasdaq biotechnology index (nbi), effective at market open on monday, december 23, 2024. “2024 has been a transformational year for mindmed. we've successfully executed many important milestones, including raising approximately $250 million.
MNMD Ratings Summary
MNMD Quant Ranking